Oncology

Latest News

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

The FDA has granted approval to pembrolizumab for the treatment of adult patients with resectable, locally advanced HNSCC whose tumors express PD-L1 with a CPS of ≥1.

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

The study identified several molecular markers related to SCLC prognosis by integrating somatic mutation profiles, mRNA transcriptome data, and clinical information. | Image credit: vitstudio - stock.adobe.com

Novel Biomarkers May Inform Prognosis in SCLC

By AJMC Contributor

June 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

May 15th 2014

Protecting Bone Health During Cancer Care

Mary K. Caffrey

NCCN Guidelines Updates

May 15th 2014

New NCCN Prostate Cancer Screening Guidelines Aim for Middle Ground

Mary K. Caffrey

NCCN Guidelines Updates

May 15th 2014

The Big Data Revolution: From Drug Development to Better Health Outcomes?

May 15th 2014

Understanding Which Therapy Comes First in Treating Castration-Resistant Prostate Cancer

Mary K. Caffrey

NCCN Guidelines Updates

May 15th 2014

NCCN Panel Asks What ACA Means to Cancer Care Delivery

Mary K. Caffrey

NCCN Guidelines Updates

May 15th 2014

Stem Cells Create a Therapeutic Niche

Surabhi Dangi-Garimella, PhD

May 15th 2014

Cheap and Easy-To-Use Diagnostic Tests to Detect Disease Biomarkers, Including Cancer

Surabhi Dangi-Garimella, PhD

May 15th 2014

The Double Whammy of the Obesity Epidemic: Increased Susceptibility to Cancer

Surabhi Dangi-Garimella, PhD

May 15th 2014

Fast Track for Prima Biomed's CVac Clinical Trial Development Program

Surabhi Dangi-Garimella, PhD

May 14th 2014

The University of Chicago Cancer Center Awarded Nearly 4 Million by the NCI

University of Chicago's Comprehensive Cancer Center received $3.9 million from the NCI as the Lead Academic Participating Site for the new NCTN initiative.

May 14th 2014

MedImmune and Incyte Announce Immuno-Oncology Collaboration

MedImmune and Incyte are planning the initiation of a collaborative Phase I/II study to test the efficacy of MedImmune's PD-L1 inhibitor MEDI4736 with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

May 14th 2014

NICE Prevents Use of Zytiga Prior to Chemotherapy

Britain's healthcare cost-effectiveness agency, NICE, has recommended against using Zytiga in chemotherapy-naive prostate cancer patients.

May 13th 2014

Ethnicity and Socioeconomic Status Determine Breast Cancer Susceptibility

A study published in the journal Breast Cancer Research and Treatment identified increased incidence of triple negative breast cancer in black women compared to white women, while those with Asian heritage were found more susceptible to HER2-positive breast cancer.

May 12th 2014

Sequenta's MRD Detection Test Predicts Post-Transplant Relapse and Survival in ALL

Sequenta's ClonoSIGHT that uses next generation sequencing to detect minimal residual disease, provides prognosis on relapse and survival of post-transplant ALL patients.

May 12th 2014

Taiho Oncology's Drug for Refractory Metastatic CRC Improves OS in Phase III Trials

Having met the primary endpoint of overall survival in it's Phase III trial of TAS-102 for refractory metastatic CRC, Taiho plans regulatory submissions.

May 12th 2014

In The Literature: A Promising New Antigen Target in Multiple Myeloma

May 12th 2014

ASCO Releases New Resources for Cancer Management in Obese Patients

ASCO today released new resources to help physicians manage the complications of obesity in patients with cancer and facilitate communication about the importance of weight management and making healthy lifestyle choices following a cancer diagnosis.

May 9th 2014

In The Literature: Using a Patient's Immune Cells to Treat Metastatic Cholangiocarcinoma

Researchers identified tumor-infiltrating CD4+ T cells specific for a mutated antigen expressed by a tumor from a patient with metastatic cholangiocarcinoma. Infusion of this patient with an expanded-population, mutation-specific T cell resulted in tumor regression and stabilization of disease.

May 9th 2014

Bipartisan Hearing Held in the Senate to Improve Federal Funding for the NCI

The American Cancer Society Cancer Action Network (ACS CAN) initiated an advertising campaign earlier this week to emphasize the importance of federal dollars in the fight against the deadly disease.

May 8th 2014

Walgreens-Komen Foundation Collaborate to Raise $15 Million for Breast Cancer

May 8th 2014

Active Surveillance Economical Over Immediate Treatment for Low-Risk Prostate Cancer

Researchers in Canada have developed a model to simulate the cost of active surveillance versus immediate treatment among low-risk prostate cancer patients.

May 8th 2014

LDL Can Help Promote Cancer Metastasis

Researchers have identified that other than clogging the arteries, LDL can also promote metastatic cancer cells, which break away from the parent tumor, to reattach at distant site.

May 8th 2014

Despite Costs, Cancer Treatment Spending Moderates

Katie Sullivan, MA

Cancer treatments are evolving to work more effectively, but consequently, their costs are rising. In 2013, cancer medicine spending reached $91 billion globally-up from $71 billion in 2008.

May 7th 2014

Myriad and UHC Sign a 3-year Contract for the myRisk Hereditary Cancer Test

The molecular diagnostic testing company Myriad Genetics announced that it had signed a 3-year contract with UnitedHealthcare to make their myRisk cancer susceptibility test accessible to patients.

May 7th 2014

Merck's PD-1 Antibody for Metastatic Melanoma to Get Priority Review

Merck announced that the FDA has granted a priority review for it's anti-PD-1 antibody, MK-3475, under the accelerated approval program, for the treatment of metastatic melanoma.

May 7th 2014

Phone App For Melanoma Screening to be Tested at MD Anderson

DermoScan, created by an engineering faculty at the University of Houston, can help screen for melanoma. It has already been used to diagnose a dermal bacterial disease in Africa, in a NIH-sponsored study.

May 6th 2014

New Biomarker Identified for Esophageal Cancer

A new biomarker for esophageal cancer shows promise in improving screening for this deadly disease and its precursor, Barrett's esophagus.

May 6th 2014

Bone Marrow-On-A-Chip: New Method to Evaluate Toxicity

Bioengineers at Harvard have devised a chip with bone marrow to test chemotherapy and radiation-associated toxicity, bypassing the need to use animal models.

May 6th 2014

Cryoablation of Early Breast Cancer Tumors

Cryotherapy, already being used for benign breast tumors and several other cancers, might prove effective in women with breast cancer tumors 1 cm or smaller in size.

May 5th 2014

Phase 3 PROCEED Trial of Vintafolide Halted

Vintafolide, jointly being developed by Merck and Endocyte, failed to present efficacy on PFS in Phase 3 trials, resulting in early termination.

...

162 163 164 165 166 167 168 169 170

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions